Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, University of Utah Health, Salt Lake City, and the Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Intermountain Healthcare, Murray, Utah; and the Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Corresponding author: Ann M. Bruno, MD, Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, University of Utah Health, Salt Lake City, UT; email: [email protected].
Financial Disclosure Torri D. Metz reports receiving UpToDate royalties for two topics on trial of labor after cesarean. Money was paid to her institution as a site PI for a preeclampsia point-of-care test. Her institution received money to conduct the study, which ended in August 2020. Money was paid to her institution from Pfizer—she was a site PI for a phase III respiratory syncytial virus vaccine trial. She is a member of the Pfizer Medical Advisory Board (January 15, 2021) and site PI for a COVID-19 vaccination trial in pregnancy. She has served on the Society for Maternal-Fetal Medicine Board of Directors. The other authors did not report any potential conflicts of interest.
Dr. Metz, Associate Editor (Obstetrics) of Obstetrics & Gynecology, was not involved in the review or decision to publish this article.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews and author correspondence are available at https://links.lww.com/AOG/C795.